Login / Signup

Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy.

Gemma RossiMaria Chiara PetroneMarco Schiavo LenaLuca AlbarelloDiego PalumboSabrina Gloria Giulia TestoniLivia ArchibugiMatteo TacelliPiera ZaccariGiuseppe VanellaLaura ApadulaStefano CrippaGiulio BelfioriMichele ReniMassimo FalconiClaudio DoglioniFrancesco De CobelliAndrew J HealeyGabriele CapursoPaolo Giorgio Arcidiacono
Published in: DEN open (2022)
RFA causes histologically evident damage with coagulative necrosis of a few millimeters in 80% of ex-vivo PDAC samples after chemotherapy and no clinical or pre-operative CT features can predict efficacy. Power settings do not correlate with the histological ablation area. These results are of relevance when employing RFA in vivo and planning clinical trials on its role in PDAC patients.
Keyphrases